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Available online 30 December 2015The KCL038 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Ethics The hESC line KCL038 is derived under license from the UK
Human Fertilisation and Embryology Authority (research li-
cence numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Commit-
tee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the ex-
periments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.
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138 C. Miere et al. / Stem Cell Research 16 (2016) 137–139arm of chromosome 5q13.2. The deletion represents benign
copy number variant.P Array No abnormalities detected Canham et al. (2015)
NA ﬁngerprint Allele sizes (in bp) of 16 microsatellite markers speciﬁc for
chromosomes 13, 18 and 21 Jacquet et al. (2013)
LA typing HLA-A 03,11; B 07,15; Bw 06; C 03,07; DRB1 14,15; DRB3
02; DQB1 05,06 Jacquet et al. (2013), Canham et al. (2015)
iability testing Pass
ycoplasma Negative
erility Pass
luripotent markers
(immunostaining)
(Fig. 1)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityhree germ layers
differentiation
in vitro
(immunostaining)
(Fig. 2)Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)bling lines
availableNoWe generated KCL038 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation
potential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed deletion of approximately 683 kb
from band q13.2 in the long arm of chromosome 5 (69,705,561 –
70,388,844). The deletion represents benign copy number variant.
The KCL038 line is conﬁrmed by PCR to be negative for Human
Immunodeﬁciency Virus 1 (HIV1), and Hepatitis C Virus (HepC, HCV).
We did not retest the line.
We also generated research grade of KCL038 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form
to the in vitro fertilization (IVF) patients if they opted to donate to
research embryos that were stored for 5 or 10 years. They mail signed
consent back to us and that might be months after the PIS and consent
were mailed to them. If in meantime new versions of PIS/consent areipotency markers. Pluripotency is conﬁrmed by immunostaining (Oct
odamine-phalloidin (red), are present in both feeders and hES cell coimplemented, we do not send these to the patients or ask them to
re-sign; the whole process is done with the version that was given
them initially. The PIS/consent documents (FRO-V.6) were created
on Dec 18, 2008. HFEA Code of Practice that was in effect at the time
of document creation: Edition 7 – R.4 (http://www.hfea.gov.uk/2999.
html). The donor couple signed the consent on Jan 12, 2010. HFEA
Code of Practice thatwas in effect at the timeof donor signature: Edition
8—R.1. HFEA Code of Practice Edition 7—R.4 was in effect: 02 Oct 2008–
30 Sep 2009, whereas 8—R.1 was in effect: 01 Oct 2009–06 Apr 2010.3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
lonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.7. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.8. SNP array
SNP array was performed as described in details (Canham et al.,
2015).
3.9. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
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